Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

Lúcia Mamede; Roser Cantenys Sabà; Samya Van Coillie; Johan Prévot; Silvia Sánchez-Ramón; POLI HARLOWE, MARIA CECILIA BERTA; Anne Barasa; Björn W. Schuller; Ayal Hendel; Nicolas Garcelon; Cornelis Boersma; Pamela Lee; Claire Booth; Luigi D. Notarangelo; Jose Drabwell; Nicholas L. Rider; Frank J. T. Staal; Siobhan O. Burns; Martin Van Hagen; Martine Pergent

doi:10.3389/fimmu.2025.1596971

Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

Journal

Frontiers in Immunology

ISSN

1664-3224

Date Issued

2025-06-17

Author(s)

Lúcia Mamede

Roser Cantenys Sabà

Samya Van Coillie

Johan Prévot

Silvia Sánchez-Ramón

POLI HARLOWE, MARIA CECILIA BERTA

Facultad de Medicina Clínica Alemana Universidad del Desarrollo

Anne Barasa

Björn W. Schuller

Ayal Hendel

Nicolas Garcelon

Cornelis Boersma

Pamela Lee

Claire Booth

Luigi D. Notarangelo

Jose Drabwell

Nicholas L. Rider

Frank J. T. Staal

Siobhan O. Burns

Martin Van Hagen

Martine Pergent

Jacques G. Rivière

Nizar Mahlaoui

Type

journal-article

DOI

10.3389/fimmu.2025.1596971

URL

https://hdl.handle.net/123456789/11350

Abstract

IntroductionThe International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.MethodsThis edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.ResultsThese discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.DiscussionThese discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient’s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.

Cite this document

Mamede, L., Sabà, R. C., Van Coillie, S., Prévot, J., Sánchez-Ramón, S., Poli, C., Barasa, A., Schuller, B. W., Hendel, A., Garcelon, N., Boersma, C., Lee, P., Booth, C., Notarangelo, L. D., Drabwell, J., Rider, N. L., Staal, F. J. T., Burns, S. O., Van Hagen, M., … Mahlaoui, N. (2025). Navigating disruption in the PID landscape: Embracing opportunities and anticipating threats in the next ten years. Frontiers in Immunology, 16, 1596971. https://doi.org/10.3389/fimmu.2025.1596971